Search

A 75-year-old man experienced hallucinations and confusion while being treated with oxycodone and buprenorphine for neuropathic pain. His medical history included diabetic foot ulcers, prostatic hypertrophy, diabetes, raised intra-ocular pressure, and atrial fibrillation. After switching to pregabalin and doxazosin, his neuropathic pain improved following the adverse reactions to the initial medications. [Extracted from the article]

A study conducted at the First Affiliated Hospital of Wenzhou Medical University in China explored the effectiveness of psychological nursing interventions for patients with prostatic hyperplasia during treatment. The study analyzed clinical data from 110 patients and divided them into a research group and a control group. The research group received psychological nursing intervention in addition to conventional nursing care, while the control group received only conventional care. The results showed that the research group had a higher treatment compliance rate, lower anxiety and depression scores, improved quality of life, and better sleep compared to the control group. The study suggests that psychological nursing intervention can effectively improve patient outcomes and the nurse-patient relationship. [Extracted from the article]

A recent study conducted by researchers at Zabol University of Medical Sciences in Iran examined the effects of heat stress and long photoperiod on the prostate of rats. The study divided thirty adult male rats into three groups: a control group, a temperature group exposed to heat, and a light group exposed to a longer day/night cycle. The researchers found that heat stress resulted in a significant decrease in testosterone levels and transformed prostate tissue. The study concluded that the ventral lobe of the prostate should be given more consideration in the study of prostatic hyperplasia. [Extracted from the article]

The article presents new findings on benign prostatic hyperplasia (BPH) and its impact on quality of life, highlighting improvements in quality of life scores following medical and surgical treatments. Topics include the use of the International Prostate Symptom Score (IPSS), the correlation between symptom severity and quality of life, and the effectiveness of different treatment approaches.

A study conducted at the Nobel Medical College Teaching Hospital in Nepal examined the correlation between the Visual Prostate Symptom Score (VPSS) and the International Prostate Symptom Score (IPSS) in patients with symptomatic benign prostatic hyperplasia (BPH). BPH affects approximately 6% of the male population and is most common in men over 50 years old. The study found that the VPSS was equally effective as the IPSS in assessing symptom severity in cases of BPH presenting with lower urinary tract symptoms. All parameters of the VPSS were significantly correlated with the IPSS. [Extracted from the article]

A recent report from researchers at Shanghai Jiao Tong University School of Medicine discusses the role of myofibroblast buildup and prostatic fibrosis in the development of benign prostatic hyperplasia (BPH). The researchers found that tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, has the potential to inhibit prostatic stromal fibroblast proliferation and the fibrosis process associated with BPH. The study also revealed that tadalafil suppressed the secretion of FGF9 and improved the expression of miR-3126-3p through the suppression of TGFb1. Overall, the findings suggest that tadalafil can inhibit pro-fibrotic signaling in the prostatic stroma. [Extracted from the article]

A recent study conducted on human benign prostatic hyperplasia (BPH) found that macrophages, a type of immune cell, play a role in increasing prostate size. The study used single-cell RNA sequencing to analyze macrophage subpopulations in large and small prostates. The researchers discovered that macrophages with altered lipid metabolism pathways, identified by the expression of TREM2 and MARCO genes, accumulate in larger prostates. These lipid-rich macrophages were found to promote cell proliferation in the prostate. The findings suggest that targeting these macrophages could potentially be a therapeutic approach for BPH. However, it is important to note that this study is a preprint and has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Medical College and Hospital Kolkata in West Bengal, India, examined the prevalence of sexual dysfunction in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). The study included 106 patients, with 56 undergoing medical treatment and 50 undergoing transurethral resection of the prostate (TURP). The researchers found that the severity of sexual dysfunction correlated with the severity of LUTS, and that treatment of LUTS improved erectile dysfunction (ED) but was associated with deterioration of ejaculatory dysfunction (EJD). The study concluded that TURP treatment resulted in a deterioration of ejaculatory function compared to medical treatment. [Extracted from the article]

A research study conducted by Chungnam National University in South Korea has explored the potential effects of Ageratum conyzoides extract (ACE) on benign prostatic hyperplasia (BPH). BPH is a condition characterized by an enlarged prostate gland. The study found that ACE significantly improved BPH characteristics in a rat model, including reducing prostate weight and thickness, as well as suppressing androgens and related hormones. The researchers concluded that ACE shows promise as an alternative phytotherapeutic agent for treating BPH. Further information on the study can be found in the journal article "Ageratum conyzoides Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia via Inhibiting Proliferation, Inflammation of Prostates, and Induction of Apoptosis in Rats." [Extracted from the article]

A study conducted in Fujian, China evaluated the efficacy of Transurethral Holmium Laser Enucleation of the Prostate (HoLEP) in the treatment of benign prostatic hyperplasia (BPH) in patients aged 75 years or less. The study included 80 patients with BPH, with 30 cases undergoing HoLEP with preservation of the urethral ridge and 50 cases undergoing conventional HoLEP. The analysis showed no significant differences in various factors between the two groups, except for the immediate postoperative urinary control rate and the incidence of retrograde ejaculation, which were better in the group that underwent HoLEP with preservation of the urethral ridge. The study concluded that this technique is comparable to conventional HoLEP but can improve urinary control and reduce the incidence of retrograde ejaculation. [Extracted from the article]

A clinical trial, NCT06511141, is currently underway to assess the effectiveness and safety of the Axonics SNM System for treating overactive bladder in male patients who have undergone prostate cancer treatment or surgical intervention for benign prostatic hyperplasia. The trial aims to evaluate the device's impact on quality of life and reduction in urinary urgency incontinence episodes. The study, conducted by Axonics, Inc., plans to enroll 120 male participants and is expected to be completed by June 30, 2026. This document provides information on the study's objectives, eligibility criteria, and contact details for those interested in participating. [Extracted from the article]

A study conducted by researchers at Weill Cornell College of Medicine evaluated the use of an artificial intelligence language generator called ChatGPT in providing patient education about benign prostatic hyperplasia (BPH). The researchers found that ChatGPT was able to generate responses that were accurate, comprehensive, and contemporary in categories such as diagnosis and pathophysiology, but it fell short in areas like relative medical treatments and procedural treatments. The study highlights the need for critical examination of all sources of patient information, including AI tools like ChatGPT, to identify areas of improvement. [Extracted from the article]

A recent study found that active surveillance is a safe and effective management strategy for favorable-risk prostate cancer. The study followed 2,155 men with localized prostate cancer who underwent periodic testing and biopsies. After 10 years, 43% of the men had their cancer reclassified to a higher grade, but only 1.4% experienced cancer spread and 0.1% died from it. Another study found that statin use is safe and effective for reducing cardiovascular risk in adults over the age of 75. Additionally, men with lower urinary tract symptoms (LUTS) may have a greater likelihood of developing cognitive problems. A study found that those with LUTS had lower cognitive scores in various domains. Lastly, consuming a healthy plant-based diet, including whole fruits, vegetables, and whole grains, may lower the risk of gout. [Extracted from the article]

A new study conducted by researchers in the Department of Urology in Tokyo, Japan, examined the effects of combining an alpha 1-blocker therapy with the b3-adrenoceptor agonist vibegron for treating overactive bladder symptoms in patients with benign prostatic hyperplasia (BPH). The study included 43 patients with BPH whose symptoms were not adequately controlled by alpha 1-blocker treatment. The combination therapy of vibegron and alpha 1-blocker significantly improved overactive bladder symptoms and sexual satisfaction. However, no significant differences were observed in other measures such as prostate symptom score, erection hardness, residual urine volume, and hormone levels. This study suggests that vibegron and alpha 1-blocker combination therapy may be effective in improving overactive bladder symptoms and sexual satisfaction in patients with BPH. [Extracted from the article]

A recent report from the National University of Medical Sciences (NUMS) discusses a study on the preventive role of Nebivolol and Alpha Tocopherol in testosterone-induced benign prostatic hyperplasia in rats. The study involved 150 male rats divided into five groups, and the researchers measured the prostatic index and prostate-specific antigen levels in each group. The results showed that the combination of Nebivolol and Alpha-Tocopherol significantly reduced the prostatic index and prostate-specific antigen levels. This research provides valuable insights into potential treatments for prostatic hyperplasia. [Extracted from the article]

A recent report from the University of California discusses the feasibility of using catheter-free water vapor thermal therapy (WVTT) to treat benign prostatic hyperplasia (BPH). The study involved 20 male patients aged 40-80 who underwent WVTT at a single academic institution. The results showed that WVTT improved voiding parameters and symptom scores without significant changes in sexual function or complications. Only one patient required postoperative catheterization within 30 days. This research provides evidence that catheter-free WVTT is a feasible treatment option for BPH. [Extracted from the article]

A new study conducted by the Center for Evidence-Based and Translational Medicine explores the association between biological aging and the risk of benign prostatic hyperplasia (BPH). The study analyzed data from a large prospective cohort of 135,933 males without BPH at enrollment. The findings suggest that biological aging is an independent and modifiable risk factor for BPH. The researchers recommend active health interventions to slow biological aging, which could help mitigate the progression of prostate aging and reduce the burden of BPH. [Extracted from the article]

Researchers from Mustansiriyah University have conducted a study on prostatic hyperplasia, a condition characterized by the enlargement of the prostate gland. The study focused on the efficacy of pterostilbene, an anti-inflammatory and antioxidant compound, in treating benign prostatic hyperplasia induced by testosterone propionate. The experiment involved male rats divided into different groups receiving various treatments. The results showed that pterostilbene had significant antioxidant and anti-inflammatory properties, effectively reducing the growth of benign prostatic hyperplasia caused by testosterone propionate. This study provides valuable insights into potential treatments for this condition. [Extracted from the article]

A recent study published in Urology Case Reports discusses the potential complications of prostatic artery embolization (PAE) as a treatment for benign prostatic hyperplasia (BPH). The study highlights a case of a 62-year-old man who experienced ischemic necrosis of the penis following PAE, resulting in compromised erectile function and worsened urinary symptoms. The researchers emphasize the importance of discussing potential risks and alternatives with patients considering this treatment. This information is valuable for individuals researching BPH treatment options and seeking to understand the potential complications associated with PAE. [Extracted from the article]

A new report from King Abdulaziz University in Jeddah, Saudi Arabia provides fresh data on benign prostatic hyperplasia (BPH), a condition that affects up to 80% of men in their lifetime. BPH causes bladder outflow obstruction and lower urinary tract symptoms, impacting quality of life. The report discusses lifestyle modifications and pharmacotherapy as first-line treatments, including alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, anticholinergics, B3-agonists, and desmopressin. However, these medications have significant side effects that should be understood and discussed by both clinicians and patients. The purpose of the report is to provide an overview of the risks and side effects of commonly used medications in BPH management. [Extracted from the article]

This article provides information about a newly launched clinical trial, NCT06466369, which aims to evaluate the efficacy and safety of once daily administration of the drug tadalafil for three months in patients with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). The trial is being conducted by Al-Azhar University and is currently in the active, not recruiting stage. The study will assess the effects of tadalafil on symptoms and quality of life in patients with BPH and ED. The trial is expected to be completed by August 2024. [Extracted from the article]

A study conducted by Yonsei University in Seoul, South Korea, investigated the withdrawal effects of alpha 1-adrenergic receptor blocker (AB) or 5 alpha-reductase inhibitor (5ARI) in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) following successful combination therapy. The study enrolled 222 patients and assessed various factors such as International Prostate Symptom Score-total (IPSS-T), prostate volume (PV), maximal flow rate, and prostate-specific antigen level over a period of 24 months. The results showed that withdrawal of AB or 5ARI may be an option for patients with BPH/LUTS who are reluctant to continue combination therapy, provided they have shown improvement in IPSS-T and reduction in PV. [Extracted from the article]

A new report from researchers at Ente Ospedaliero Cantonale (EOC) in Lugano, Switzerland discusses the use of Prostate Artery Embolization (PAE) with small beads for the treatment of Benign Prostatic Hyperplasia (BPH). BPH is the most common cause of Lower Urinary Tract Symptoms (LUTSs) in elderly populations. The study evaluated 24 patients who underwent PAE treatment and found that technical success was achieved in all patients, with no major complications recorded. The researchers concluded that minimally invasive treatments like PAE are safe and effective for BPH and are gaining popularity among professionals and patients. [Extracted from the article]

A recent study conducted at a tertiary care hospital in Pakistan examined the impact of transurethral resection of the prostate (TURP) on erectile function in patients with benign prostatic hyperplasia (BPH). The study involved 261 male subjects between the ages of 50 and 70 who underwent TURP. The researchers found that TURP was associated with a decline in erectile function, as measured by the International Index of Erectile Function (IIEF) scoring system. The study highlights the importance of providing comprehensive preoperative counseling to patients considering TURP in order to inform them about the potential impacts on sexual health. [Extracted from the article]

A recent study conducted at the University of Medicine & Pharmacy Ho Chi Minh City in Vietnam has found that an extract from the Physalis angulata plant may have inhibitory effects on 5-alpha reductase, an enzyme associated with benign prostatic hyperplasia (BPH). The study evaluated the extract's effects on mouse prostate homogenates in vitro and in a mouse model of testosterone-induced BPH. The extract showed potential inhibitory effects on 5-alpha reductase and was comparable to the drug finasteride in suppressing BPH. The extract contains chlorogenic acid and rutin as its main components, with chlorogenic acid showing inhibitory effects on 5-alpha reductase. The presence of chlorogenic acid in the extract may explain its inhibitory effects on BPH. [Extracted from the article]

A new study conducted by researchers at Sun Yat-sen University in Guangzhou, China, explores the use of commercial oral poly-herbal traditional Chinese medicine (TCM) formulations combined with Western medicine (WM) in the treatment of benign prostatic hyperplasia (BPH). The study conducted a network meta-analysis of 107 randomized controlled trials (RCTs) involving 11,037 patients to assess the effectiveness of various formulations. The results suggest that combining oral poly-herbal TCM formulations with WM may provide greater therapeutic benefits in BPH treatment compared to WM alone. However, further empirical studies are needed to confirm these findings. [Extracted from the article]

A case report from the Institute of Urology and Nephrology discusses the presence of scrotal calcinosis cutis, a nonmalignant condition characterized by nodules on the scrotum, in a patient with benign prostatic hyperplasia (BPH). The patient declined open surgical intervention for the scrotal condition due to fear of genital mutilation, despite the recommendation for surgical therapy. The report emphasizes the importance of respecting the patient's opinion and highlights the various treatment options available for scrotal calcinosis cutis. The surgical option is favored due to its lower chances of recurrence. [Extracted from the article]

A recent study conducted by researchers at Kansai Gaidai University in Japan explores how Japanese men understand and express their experiences with benign prostate enlargement and prostate cancer. The study used in-depth interviews to analyze the participants' perspectives on the body, gender, and sexuality in relation to these conditions. The findings suggest that Japanese men may struggle with somatic knowledge, experience emasculation, and face challenges related to sexuality and sexual reputation. The study provides insights into the cultural and social factors that influence the perception and management of prostate-related conditions in contemporary Japan. [Extracted from the article]

A recent study conducted by researchers from the Department of Surgery focuses on the management of benign prostatic hyperplasia (BPH) using patient-reported outcomes (PROs). The study aims to integrate enhanced PROs into routine clinical practice to better capture the spectrum of lower urinary tract symptoms (LUTS) in older men with BPH. By employing comprehensive PRO measures, the study hopes to refine symptom assessment and enhance treatment monitoring, potentially leading to improved personalized care strategies. The findings could have significant implications for clinical practices and better health management strategies for men with LUTS/BPH. [Extracted from the article]

A study conducted at Comenius University in Martin, Slovakia, investigated the effect of combining pelvic floor muscle training with the urgency suppression technique (PFMT-st) and silodosin in men with benign prostatic hyperplasia (BPH) and overactive bladder (OAB). The study found that the addition of PFMT-st to silodosin treatment significantly improved OAB symptoms in men with BPH. This research suggests that PFMT-st should be considered as the first-choice treatment for OAB in BPH. The study was supported by the European Union and has been peer-reviewed. [Extracted from the article]

A study conducted at the Chinese University of Hong Kong evaluated the use of transurethral water vapour thermal therapy (WVTT) under local anesthesia alone for the treatment of benign prostatic enlargement in Chinese patients. The study included 50 Chinese patients who underwent the procedure between June 2020 and December 2021. The results showed that WVTT is a safe and effective procedure that relieves lower urinary tract symptoms with minimal hospital stay. The researchers concluded that WVTT can be performed in an office-based setting under local anesthesia, maximizing the utilization of the surgical theater. [Extracted from the article]

Researchers at Abo Akademi University in Turku, Finland have conducted a study on prostate cancer (PCa) and benign prostatic hyperplasia (BPH), two prevalent conditions affecting a significant portion of the male population. The study explores the effectiveness of 1H NMR urine metabolomics as a non-invasive diagnostic alternative to traditional methods such as digital rectal examination (DRE) and prostate-specific antigen (PSA) tests. The researchers found that 1H NMR urine metabolomics was able to distinguish between PCa and BPH, as well as differentiate various PCa grades. The study also identified potential biomarkers for these conditions. This research provides valuable insights into early detection and patient-specific treatment strategies for PCa and BPH. [Extracted from the article]

A recent study conducted at Wuhan University in Hubei, China, explored the diagnostic value of a tripartite magnetic resonance imaging (MRI) model for prostatitis, prostatic hyperplasia, and prostate cancer. The study included 100 patients with prostatic diseases, and the results showed that the tripartite MRI model, which combines T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging, had high diagnostic accuracy and outperformed other diagnostic methods. The researchers concluded that this model could be valuable in clinical applications due to its high sensitivity and low misdiagnosis rate. The study was published in the International Journal of Radiation Research and was supported by the Wuhan Health Research Fund. [Extracted from the article]

Researchers at Michael Okpara University of Agriculture have published a new report on prostatic hyperplasia. The study investigated the effects of Syzygium malaccense methanol leaf extract (SMLE) on testosterone-estradiol valerate induced benign prostatic hyperplasia (BPH) in rats. The results showed that SMLE modulated various biochemical and inflammatory markers, as well as prostate histology, suggesting that it could be useful in the management of BPH. The study also found that SMLE exhibited strong antioxidant activity. [Extracted from the article]

Researchers from the London School of Hygiene and Tropical Medicine have conducted a study on the use of five-alpha reductase inhibitors (5ARIs) in the management of benign prostatic hyperplasia (BPH) and its potential association with prostate cancer risk. The study analyzed data from 77,494 men with newly diagnosed BPH and found that the incidence rate of prostate cancer was lower among those treated with 5ARIs compared to those treated with alpha blockers or no pharmacological treatment. However, the reduced risk seemed to be driven by cases diagnosed within a year of BPH, possibly reflecting misdiagnosed prevalent prostate cancers. After excluding the first year after BPH diagnosis, there was little evidence of a reduced prostate cancer risk in those taking 5ARIs. [Extracted from the article]

This article is an anthology of poems titled "Approaching Seventy" by Pesach Rotem. The poem reflects on the author's experience of feeling left behind by the advancements of the world as they age. They express a lack of familiarity with modern terms and cultural references such as memes, influencers, and popular musicians. However, they also highlight the value of gaining knowledge and learning new things as they age. [Extracted from the article]

A study conducted by researchers at the University of Brawijaya aimed to determine the prevalence of urinary tract stones in patients with benign prostatic hyperplasia (BPH) undergoing trans urethral resection of the prostate (TURP) surgery. The study analyzed medical records of 169 BPH patients who underwent TURP at Saiful Anwar General Hospital from 2018 to 2022. The results showed that 20.7% of the patients had urinary tract stones, indicating an absolute indication for TURP. The study provides valuable information on the prevalence of urinary tract stones in BPH patients undergoing TURP surgery. [Extracted from the article]